Phospholipid, arachidonate and eicosanoid signaling in schizophrenia

OCL - Oilseeds and fats, Crops and Lipids

Volumn 23, Issue 1, 2016, Pages

  Messamore, Erik ^a   Yao, Jeffrey K ^b,c,d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Arachidonic acid; Eicosanoids; Niacin induced flushing, endophenotype marker; Phospholipids; Schizophrenia

Indexed keywords

EID: 85000366274     PISSN: 22726977     EISSN: 22576614     Source Type: Journal    
DOI: 10.1051/ocl/2015054     Document Type: Article

References (95)

1. Akhondzadeh S, Tabatabaee M, Amini H, et al. 2007. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90: 179-185.
2. Arvindakshan M, Sitasawad S, Debsikdar V, et al. 2003. Essential polyunsaturated fatty acid and lipid peroxide levels in nevermedicated and medicated schizophrenia patients. Biol. Psychiatry 53: 56-64.
3. Bazan NG. 2006. Eicosanoids, docosanoids, platelet-activating factor and inflammation. In: Siegel GJ, Albers WR, Brady ST, Price DL, eds., Basic neurochemistry: Molecular, cellular, and medical aspects. 7th ed., Burlington, MA: Academic Press, pp. 575-591.
4. Bentsen H, Solberg DK, Refsum H, et al. 2011. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol. Psychiatry 70: 97-105
5. Benyó Z, Gille Z, Kero J, Csiky M, et al. 2005. GPR109A (PUMAG/ HM74A) mediates nicotinic acid induced flushing. J. Clin. Invest. 115: 3634-3640.
6. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. 2006. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharmacol. 70: 1844-1849.
7. Berger G, Yuen H, McGorry P. 2002. The topical niacin flush test in early psychosis (Abstract). Schizophr. Res. 53: S38.
8. Berman KF, Torrey EF, Daniel DG, Weinberger DR. 1992. Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch. Gen. Psychiatry. 49: 927-934.
9. Bleuler E. 1920. Lehrbuch der Psychiatrie, Berlin: Springer reprinted English translation (1976) Textbook of psychiatry. New York: Arno Press.
10. Bosveld-van Haandel L, Knegtering R, Kluiter H, van den Bosch RJ 2006. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res. 143: 303-306.
11. Braff DL, Freedman R, Schork NJ, Gottesman II. 2007. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33: 21-32.
12. Chang, S. S., Liu, C. M., Lin, S. H., et al. 2009. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 35: 213-221.
13. Condray R, Yao JK. 2011 Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. S3: 298-330.
14. Conklin SM, Muldoon MF, Reddy RD, Yao JK. 2007. Fatty acids and psychiatric disorders. In: Chow C. K. ed., Fatty acids in foods and their health implications, 3rd ed. New York: Marcel Dekker, Inc., pp. 1229-1256.
15. Das I, Khan NS. 1998. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostagland. Leukot. Essent. Fatty Acids 58: 165-168.
16. Davis GC, Buchsbaum MS, van Kammen DP, Bunney WE Jr. 1979. Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry Res. 1: 61-69.
17. Doris AB, Wahle K, MacDonald A, et al. 1998. Red cell membrane fatty acids, cytosolic phospholipase A2 and schizophrenia. Schizophr. Res. 31: 185-196.
18. EatonWW, Hayward C, Ram R. 1992. Schizophrenia and rheumatoid arthritis: a review. Schizophr. Res. 6: 181-192.
19. Eklund B, Kaijser L, Nowak J, Wennmalm A. 1979. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17: 821-830.
20. Garver DL, Holcomb JA, Christensen JD. 2000. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J. Clin. Psychiatry 61: 964-972.
21. Glen AI, Glen EM, Horrobin DF, et al. 1994. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12: 53-61.
22. Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. 1996. Membrane fatty acids, niacin flushing and clinical parameters. Prostagland. Leukotr. Essent. Fatty Acids 55: 9-15.
23. Hoffer A. 1962. Niacin therapy in psychiatry. Springfield, IL: Charles Thomas.
24. Hoppman RA, Peden JG, Over SK. 1991. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Arch. Intern. Med. 151: 1309-1313.
25. Horrobin DF. 1977. Schizophrenia as a prostaglandin deficiency disease. Lancet 1: 936-937.
26. Horrobin DF. 1980a. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Orthomol. Psychiatry 91: 33-34
27. Horrobin DF. 1980b. Schizophrenia: a biochemical disorder Biomedicine 32: 54-55.
28. Horrobin DF. 1998. The membrane phospholipid hypothesis as a biochemical basis for the neuro-developmental concept of schizophrenia. Schizophr. Res. 30: 193-208.
29. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. 1991. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30: 795-805.
30. Hudson CJ, Kennedy JL, Gotowiec A, et al. 1996. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr. Res. 21: 111-116.
31. Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ. 1997. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia. Biol. Psychiatry 41: 507-513.
32. Jablensky A. 2006 Subtyping schizophrenia: implications for genetic research. Mol. Psychiatry 11: 815-836.
33. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. 2008. Schizophrenia, just the facts: what we know in 2008 Part 3: neurobiology. Schizophr. Res. 106: 89-107.
34. Khanna N, Altmeyer W Zhuo J, Steven A. 2015 Functional neuroimaging: Fundamental principles and clinical applications. Neuroradiol. J. 28: 87-96.
35. Kobza Black A, Greaves MW, Hensby CN. 1982. The effect of systemic prednisolone on arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous inflammation. Br. J. Clin. Pharmacol. 14: 391-394.
36. Kop PG, Zhang D., Gauthier KM, et al. 2010. Adrenic acid metabolites as endogenous endothelium-derived and zona glomerulosaderived hyperpolarizing factors. Hypertension 55: 547-554.
37. Laan W, Grobbee, D, Selten JP, Heijnen CJ, Kahn RS, Burger H. 2010. Adjuvant asprin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 71, 520-527.
38. Lai, E, De Lepeleire, I, Crumley, TM, et al. 2007. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81: 849-857.
39. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. 1992. Patterns of cerebral blood flow in schizophrenia Brit. J. Psychiatry 160: 179-186.
40. Lin SH, Liu CM, Chang SS, et al. 2007. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr. Bull. 33: 174-182.
41. Liu CM, Chang SS, Liao SC, et al. 2007. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatr. Res. 152: 181-187.
42. Maciejewski-Lenoir D., Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. 2006. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126: 2637-2646.
43. Maclean R, Ward PE, Glen I, Roberts SJ, Ross BM, 2003. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27: 927-933.
44. Mahadik SP, Yao JK. 2006. Phospholipids in schizophrenia. In: Lieberman, J. A., Stroup, T. S., and Perkins, D. O. eds. Textbook of schizophrenia. Washington, DC: The American Psychiatric Publishing, Inc., pp. 117-135.
45. Maida ME, Hurley SD, Daeschner JA, Moore AH, O'Banion MK. 2006. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 1103: 164-172.
46. Messamore E. 2003. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostagland. Leukot. Essent. Fatty Acids 69: 413-419.
47. Messamore E. 2012. Niacin subsensitivity is associated with functional impairment in schizophrenia. Schizophr. Res. 137: 180-184
48. Messamore E, Hoffman WF, Yao JK. 2010. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr. Res. 122: 248-256.
49. Miller, C. L., Dulay, J. R. 2008. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res. Bull. 77: 33-41.
50. Mills CM, Hill SA, Marks R. 1997. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol. 133: 823-902
51. Morrow JD, Parsons WG, Roberts LJ. 1989. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38: 263-274.
52. Morrow JD, Awad JA, Oates JA, Roberts LJ. 1992. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98: 812-815.
53. Müller N, Riedel M, Scheppach C, et al. 2002. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159: 1029-1034.
54. Murakami M, Kudo I. 2004. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 43: 3-35.
55. Nilsson BM, Holm G, Hultman CM, Ekselius L. 2015 Cognition and autonomic function in schizophrenia: inferior cognitive test performance in electrodermal and niacin skin flush non-responders Eur. Psychiatry 30: 8-13.
56. Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. 2000. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20: 763-770.
57. Ono N, Abiru T, Kamiya H. 1992. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostagland. Leukotr. Essent. Fatty Acids 46: 59-63.
58. Papaliodis D, Boucher W, Kempuraj D, et al. 2008. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model. J. Pharmacol. Exp. Ther. 327: 665-672.
59. Peet M. 2007. Membrane fatty acid deficit in schizophrenia and mood disorders. In: Reddy R and Yao JK eds. Fatty acids and oxidative stress in neuropsychiatric disorders. New York: Nova Science Publishers, Inc., pp. 101-114.
60. Peet M, Laugharne JDE, Horrobin DF, Reynolds GP. 1994. Arachidonic acid: A common link in the biology of schizophrenia? Arch. Gen. Psychiatry 51: 665-666.
61. Peet M, Horrobin DF, Group EEMS. 2002. A dose ranging exploratory study of the effects of ethyleicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 36: 7-18.
62. Pettegrew JW, Keshavan MS, Panchalingam K, et al. 1991. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48: 563-568.
63. Plummer NA, Hensby CN, Black AK, Greaves MW. 1977. Prostaglandin activity in sustained inflammation of human skin before and after aspirin. Clin. Sci. Mol. Med. 52: 615-620.
64. Puri BK, Easton T, Das I, Kidane L, Richardson AJ. 2001. The niacin skin flush test in schizophrenia: a replication study. Int. J. Clin. Pract. 55: 368-370.
65. Puri BK, Hirsch SR, Easton T, Richardson AJ. 2002. A volumetric biochemical niacin flush based index that noninvasively detects fatty acid deficiency in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 26: 49-52.
66. Puri BK, Richardson AJ, Counsell SJ, et al. 2007. Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy study. Prostagland. Leukot. Essent. Fatty Acids 77: 97-99.
67. Reddy RD, Keshavan MS, Yao JK. 2004. Reduced red blood cell membrane polyunsaturated fatty acids in first-episode schizophrenia at neuroleptic-naïve baseline. Schizophr. Bull. 30: 901-911.
68. Ross BM, Hughes B, Turenne S, Seeman M, Warsh JJ. 2004. Reduced vasodilatory response to methyl-nicotinate in schizophrenia as assessed by laser doppler flowmetry. Eur. Neuropsychopharma 14: 191-197.
69. Shah SH, Ramchand CN, Peet M. 1999. The niacin skin flush test: first-degree relatives show responses intermediate between patients and controls. Schizophr. Res. 36: 314.
70. Shah SH, Vankar GK, Peet M, Ramchand CN. 2000. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43: 163-164.
71. Skosnik PD, Yao JK. 2003. From phospholipid and fatty acid defects to altered neurotransmission: Is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostagland. Leukot. Essent. Fatty Acids 69: 367-384
72. Smesny S, Riemann S, Riehemann S, Bellemann ME, Sauer H. 2001. Quantitative measurement of induced skin reddening using optical reflection spectroscopy-methodology and clinical application. Biomed. Tech. (Berl). 46: 280-286.
73. Smesny S, Berger G, Rosburg T, et al. 2003. Potential use of the topical niacin skin test in early psychosis a combined approach using optical reflection spectroscopy and a descriptive rating scale. J. Psychiatr. Res. 37: 237-247.
74. Snyder SH. 1981. Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry. 138: 460-464.
75. Sussman N, Magid S. 2000. Psychiatric manifestations of nonsteroidal antiinflammatory drugs. Primary Psychiatry 7: 26-30.
76. Svedmyr N, Heggelund A, Aberg G, 1977. Influence of indomethacin on flush induced by nicotinic acid in man. Acta. Pharmacol. Toxicol. 41: 397-400.
77. Tang Y, Zhou L, Gunnet JW, Wines PG, Cryan EV, Demarest KT. 2006. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 345: 29-37.
78. Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. 2003. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 61: 1-6.
79. Turenne SD, Seeman M, Ross BM. 2001. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine, and nicotine upon nicotinic acid response Schizophr. Res. 50: 191-197
80. Urade Y, Ujihara M, Horiguchi Y, Ikai K, Hayaishi O. 1989. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143: 2982-2989.
81. Vaddadi KS, Gilleard CJ, Mindham RH Butler R. 1986. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacol. 88: 362-367.
82. Waldo MC. 1999. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40: 49-53.
83. Wanibuchi F, Usuda S. 1990. Synergistic effects between D-I and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology 102: 339-342.
84. Ward PE, Sutherland J, Glen EM, Glen AI. 1998. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29: 269-274.
85. Weinberger DR, Berman KF, Suddath R, Torrey EF. 1992. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J. Psychiatry. 149: 890-897.
86. Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J. 1982. Aspirin blocks nicotinic acid-induced flushing. Clin. Pharmacol. Ther. 31: 478-482.
87. Winklemann RK, Wilhelmj CM, Horner FA. 1965. Experimental studies on dermographism. Arch. Dermatol. 92: 436-442.
88. Yao JK. 2003. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds., Phospholipid spectrum disorders in psychiatry and neurology, 2nd ed. Lancashire, UK: Marius Press, pp. 193-212.
89. Yao JK, van Kammen DP, Welker JA. 1994a. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13: 217-226.
90. Yao JK, van Kammen DP, Gurklis J. 1994b. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 13: 227-232.
91. Yao JK, Leonard S, Reddy R. 2000. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42: 7-17.
92. Yao JK, Dougherty GG, Reddy RD, et al. 2010a. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 5: e9508.
93. Yao JK, Dougherty GG, Reddy RD, et al. 2010b. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. Mol. Psychiatry. 15: 938-953.
94. Yao JK, Dougherty Jr GG, Gautier CH, et al. 2015. Prevalence and specificity of the abnormal niacin response: A potential endophenotype marker in schizophrenia. Schizophr. Bull. DOI: 10. 1093/schbul/sbv130.
95. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignot G. 2003. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci. 6: 43-50.